Physician profile
Raya Saba
NPI 1902154743
$3,598.61
in general payments reported to CMS, 2019-2025
29 companies · $2,934 in 2025
The $2,934 reported for 2025 was more than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $125 · 2023: $141 · 2024: $399 · 2025: $2,934.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $2,345 · Food and Beverage: $1,129.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $2,345.00 |
| Food and Beverage | $1,128.61 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $2,369.56 | 2025 | Calquence, Enhertu |
| Novocure INC. | $140.90 | 2023 | Optune |
| Janssen Biotech, INC. | $125.00 | 2021 | |
| Amgen INC. | $119.68 | 2024 | Blincyto |
| Genmab U.S., INC. | $111.52 | 2024 | Epkinly |
| Glaxosmithkline, LLC. | $102.39 | 2024 | Ojjaara |
| Pfizer INC. | $83.58 | 2024-2025 | |
| Daiichi Sankyo INC. | $57.24 | 2025 | Enhertu, Datroway |
| Merck Sharp & Dohme LLC | $53.18 | 2025 | Keytruda, Welireg, Keytruda Qlex |
| Eisai INC. | $48.32 | 2025 | |
| Genentech USA, INC. | $30.61 | 2025 | Tecentriq |
| Regeneron Healthcare Solutions, INC. | $30.36 | 2025 | Libtayo |
| E.R. Squibb & Sons, L.L.C. | $25.78 | 2025 | Opdivo |
| Abbvie INC. | $24.76 | 2025 | |
| Beone Medicines USA, INC. | $24.29 | 2025 | Tevimbra |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sobi, INC | $24.24 | 2025 | |
| Exelixis INC. | $21.77 | 2025 | Cabometyx |
| Novartis Pharmaceuticals Corporation | $21.44 | 2025 | |
| Stemline Therapeutics INC. | $20.01 | 2025 | Orserdu |
| Syndax Pharmaceuticals, INC. | $19.89 | 2025 | |
| Gilead Sciences, INC. | $19.44 | 2025 | Trodelvy |
| Lilly USA, LLC | $17.85 | 2025 | Verzenio, Jaypirca |
| Incyte Corporation | $17.79 | 2025 | Jakafi, Niktimvo |
| Taiho Oncology, INC. | $17.67 | 2025 | |
| Aimmune Therapeutics, INC. | $15.99 | 2025 | Zenpep |
| Caris Mpi, INC. | $15.00 | 2025 | Mi Cancer Seek |
| Takeda Pharmaceuticals U.S.A., INC. | $14.76 | 2025 | Iclusig |
| Pharmaessentia USA Corporation | $13.82 | 2025 | Besremi |
| Pharmaand Gmbh | $11.77 | 2025 | Rubraca |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Raya Saba listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.